We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Microneedle Patch Detects Skin Cancer Early

By LabMedica International staff writers
Posted on 31 May 2024
Print article
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)
Image: Illustration of the microneedle patch (Photo courtesy of Karolinska Institutet)

Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes. Despite its advancements, there has been a lack of progress specifically in the area of cancer, and more notably in skin cancer detection. Researchers have now introduced a novel technique for identifying malignant melanoma, which is the most serious type of skin cancer and also the fastest growing.

A groundbreaking study conducted by researchers at Karolinska Institutet (Stockholm, Sweden) led to the development of a new type of patch equipped with microneedles designed to detect the biomarker tyrosinase directly within the skin. Tyrosinase is an enzyme that serves as a crucial biomarker for malignant melanoma. By assessing the enzyme directly in the skin, this approach allows for the rapid detection of changes indicative of the disease. The feasibility of this transdermal microneedle sensor for directly quantifying tyrosinase has been demonstrated in an ex vivo skin model.

In their research, scientists employed human tissue samples from healthy individuals. They applied tyrosinase to these samples to simulate the presence of skin cancer. Their findings suggest that this new patch could serve as an effective alternative to traditional diagnostic techniques, facilitating earlier detection and treatment of malignant melanoma. The researchers are optimistic that their invention will reduce the need for invasive procedures and enhance the quality of life for patients. This innovation marks a significant step forward in improving skin health monitoring and could potentially be adapted to detect other biomarkers simply by altering its design.

“Our method is less invasive and has the potential to provide faster and more reliable results compared to traditional biopsies,” said Onur Parlak, Associate Professor at Karolinska Institutet. “Our goal is to continue developing and improving this technique to offer more accurate and painless diagnostics.” 

Related Links:
Karolinska Institutet

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Macrophages infected with mycobacterium tuberculosis (Photo courtesy of MIT)

New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests

Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more